Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs, Inc. officer Stephen Stout reported acquiring additional equity through a private placement-related transaction. He acquired 12,805 shares of common stock and exercised accompanying warrants for 12,805 shares at an exercise price of $1.0846 per share, bringing his direct holdings to 93,366 common shares. These securities stem from a prior securities purchase agreement where common stock and warrants were originally issued together at a combined price of $0.8677 per share and warrant, with the warrants exercisable during a period tied to clinical data milestones for SL-325.
Shattuck Labs Inc. ownership filing reports that T. Rowe Price Investment Management, Inc. holds 9,865,558 shares of common stock, representing 13.8% of the class as shown for the period 03/31/2026. The filer states sole voting power for 9,831,415 shares and sole dispositive power for 9,865,558 shares. The filing is an amendment and is signed by a Vice President on 05/15/2026.
Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported an exercise of warrants and related share acquisition. He acquired 64,027 shares of common stock, linked to a warrant exercise covering 64,027 underlying shares at an exercise price of $1.0846 per share. Following these transactions, he directly owns 292,251 shares of common stock. No sales or dispositions were reported in this filing, and no derivative warrants remain outstanding from this grant.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported an option exercise and related share sale. He exercised stock options for 2,032 shares of common stock at an exercise price of $3.57 per share and sold 2,032 shares in an open-market transaction at a weighted average price of $7.01 per share.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 2, 2026, designed to sell shares received from option exercises only as needed to fund exercise costs and estimated tax withholding. Following these transactions, he directly holds 81,258 shares of common stock and 50,168 stock options.
Shattuck Labs, Inc. chief medical officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock. The shares were sold at a weighted average price of $6.61 per share, in multiple trades between $6.41 and $7.03. Following the transaction, she directly holds 166,219 shares. The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.
Shattuck Labs, Inc. director and Chief Executive Officer Taylor Schreiber reported acquiring 25,610 shares of common stock through the exercise of warrants at a conversion price of $1.0846 per share. Following these transactions, Schreiber holds 122,222 shares directly and 2,610,750 shares indirectly through Houghton Capital Holdings, LLC.
Shattuck Labs, Inc. executive Stephen Stout reported a small tax-related share disposition. On this Form 4, 968 shares of Common Stock were withheld at $6.85 per share to cover tax obligations, a non-market transaction. After this withholding, Stout directly holds 80,561 shares of Shattuck Labs common stock.
Shattuck Labs reported a first-quarter 2026 net loss of $14.8 million, slightly wider than $13.7 million a year earlier, as it expanded spending on its lead inflammatory bowel disease candidate SL-325. Research and development expenses rose to $10.9 million, while general and administrative costs were stable at $4.6 million.
Cash and cash equivalents increased to $90.4 million from $54.2 million at year-end 2025, helped by $20.6 million of common stock sales through an at-the-market program and $5.4 million of warrant exercises. Management believes this cash is sufficient to fund operations for at least 12 months as it completes a Phase 1 trial of SL-325 and prepares a Phase 2 trial in Crohn’s disease.